Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, ProQR Therapeutics NV revenues decreased 16% to EUR16.3M. Net loss increased 52% to EUR42.2M. Revenues reflect Revenue decrease of 16% to EUR15.9M, Other Income decrease of 31% to EUR441K. Higher net loss reflects RNA based Therapeutics segment loss increase of 43% to EUR43.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.32 to -EUR0.40.